title: A longitudinal evaluation of anti-FVIII antibodies demonstrated IgG4 subclass is mainly correlated with high-titre inhibitor in haemophilia A patients.
abstract: The development of inhibitory antibodies against factor VIII (FVIII) (inhibitor) is the major complication in haemophilia A patients. The FVIII-binding antibodies development comprises a polyclonal immunoglobulin (Ig) G response. Recent studies showed strong correlation between the presence of neutralizing anti-FVIII antibodies (inhibitors) and IgG4 subclass. The aim of this study was to evaluate anti-FVIII IgG subclasses in haemophilia A patients with inhibitor both in a cross-sectional and in a longitudinal analysis. Inhibitors were determined by Nijmegen-Bethesda assay. Anti-FVIII IgG subclasses were performed by ELISA, and samples from 20 healthy individuals were used to validate the test. We studied 25 haemophilia A patients with inhibitor, previously treated exclusively with plasma-derived FVIII concentrates or bypassing agents. The IgG subclasses distributions were evaluated in two groups of patients classified according to inhibitor response. IgG1 and IgG4 antibodies were most prominent in haemophilia A patients with inhibitors when compared with IgG2 and IgG3. This study reports for the first time the behaviour of FVIII-binding IgG1 and IgG4 subclasses in a longitudinal analysis, in a clinical setting, of high-response inhibitor haemophilia A patients, showing the correlation of IgG4 and the inhibitor titres. In spite of being considered a non-pathologic antibody subclass with anti-inflammatory properties in other situations, IgG4 is correlated with the presence of high-titre inhibitor in the haemophilia setting. The comprehension of the IgG4 role in immune response may be crucial to establish the process for designing specific tolerance to FVIII.
authors.affiliation: Hemophilia Unit 'Cláudio L. P. Corrêa', Centro de Hematologia e Hemoterapia da Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Campinas, São Paulo, Brazil.
authors.forename: S A L
authors.initials: SA
authors.lastname: Montalvão
authors.affiliation: Hemophilia Unit 'Cláudio L. P. Corrêa', Centro de Hematologia e Hemoterapia da Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Campinas, São Paulo, Brazil.
authors.forename: A C
authors.initials: AC
authors.lastname: Tucunduva
authors.affiliation: Hemophilia Unit 'Cláudio L. P. Corrêa', Centro de Hematologia e Hemoterapia da Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Campinas, São Paulo, Brazil.
authors.forename: L H
authors.initials: LH
authors.lastname: Siqueira
authors.affiliation: Hemophilia Unit 'Cláudio L. P. Corrêa', Centro de Hematologia e Hemoterapia da Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Campinas, São Paulo, Brazil.
authors.forename: A L A
authors.initials: AL
authors.lastname: Sambo
authors.affiliation: Hemophilia Unit 'Cláudio L. P. Corrêa', Centro de Hematologia e Hemoterapia da Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Campinas, São Paulo, Brazil.
authors.forename: S S
authors.initials: SS
authors.lastname: Medina
authors.affiliation: Hemophilia Unit 'Cláudio L. P. Corrêa', Centro de Hematologia e Hemoterapia da Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue, University of Campinas, Campinas, São Paulo, Brazil.
authors.forename: M C
authors.initials: MC
authors.lastname: Ozelo
mesh_terms: D000293:Adolescent; D000328:Adult; D001323:Autoantibodies / Q000276:immunology*; D002648:Child; D005169:Factor VIII / Q000276:immunology*; D005260:Female; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000145:classification* / Q000276:immunology*; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D055815:Young Adult
chemical_list: D001323:Autoantibodies; D007074:Immunoglobulin G; D005169:Factor VIII
keywords: IgG4; haemophilia; immunoglobulin; inhibitor